Endologix Presents Clinical Data at International Symposium of Endovascular Therapy.

IRVINE, Calif. -- Three-Year Preliminary Data Analysis Following Powerlink(R) Procedure Suggests Decreases in Aneurysm Sac Diameter and Volume

Endologix, Inc. (Nasdaq:ELGX) today announced that a clinical paper presented at the International Symposium for Endovascular Therapy (ISET) suggests that three years following treatment with the Company's Powerlink(R) System, patients (from the pivotal PMA study) experienced decreases in aneurysm sac diameter and volume, and less angulation of the aorta. The clinical paper, "Sac Remodeling with the Powerlink(R) Stent Graft for AAA," was presented by Dr. Rodney White, Professor of Vascular Surgery at Harbor-UCLA Medical Center, at ISET in Miami on Wednesday, January 19, 2005.

"These results are based on our retrospective study that investigated changes in aneurysm sac anatomy, including maximum diameter of the aneurysm, volume of the aneurysm sac, length from the renal arteries to the aortic bifurcation and angulation of the abdominal aorta, during a three-year period in patients treated with a Powerlink System," said Dr. White. "The design features of the Powerlink device, including its long main body, and single wire stent cage that provide for column strength, may positively influence the aortic sac remodeling that we found during this study."

Paul McCormick, president and CEO of Endologix, commented, "In spite of the success of minimally invasive treatment of AAA, there remain 50,000 to 60,000 patients who still undergo the traditional surgery, many due to concerns about the long-term results of the stent graft procedure itself. With our Powerlink System, we are addressing the failings of first-generation endoluminal stent grafts in deliverability of the device, dependability of the clinical results and durability of the materials. If the data demonstrates that the Powerlink design induces this favorable remodeling it may provide greater long-term benefit for the therapy permitting it to be applied to a larger patient population.

"Based on its design benefits, we are working to make the Powerlink System the standard of care," added Mr. McCormick. "Additionally, we are pleased to further establish our position of industry leadership and product innovation."

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the United States. In October 2004, Endologix received approval to market the Powerlink in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties, including risks related to the clinical success and customer acceptance of a new medical device product, and the risks related to intellectual property rights surrounding medical device technology, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix, all as more fully described in the risk factors and other matters set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2003, and the Company's other filings with the SEC.